Business Wire

Biognosys and NeoGenomics Expand Global Strategic Partnership Initiatives on Multiple Discovery Proteomics Solutions Supporting Biopharma R&D

11.4.2022 15:00:00 EEST | Business Wire | Press release

Share

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today a global strategic partnership agreement with NeoGenomics, Inc. (Nasdaq: NEO), a leading provider of oncology testing and global contract research services. The strategic partnership will encompass multiple strategic and commercial initiatives, including NeoGenomics labs offering access to Biognosys proteomics platforms, medical and scientific affairs-joint presentations and discussions, along with joint scientific and technical initiatives.

“At Biognosys, we continuously push the boundaries of what is possible with our proteomics solutions to address key challenges in drug development,” said Kristina Beeler, Ph.D., Chief Business Officer, Biognosys. “Our platforms are transforming research from early drug discovery to clinical biomarker identification. We are excited to now combine our proteomics platforms with NeoGenomics’ immuno-profiling platform to advance our biopharma partners’ oncology drug development programs.”

One of the first efforts of this collaboration saw Biognosys combining its TrueDiscovery™ proteomics platform with NeoGenomics’ MultiOmyx™ multiplexed immunofluorescence (mIF) spatial tissue analysis as a multimodal approach for analyzing the proteins of tumor samples from late-stage melanoma patients treated with immune-checkpoint inhibitors. The dual proteomic and mIF profiling approach allows for a comprehensive characterization of melanoma patients and pinpointed a specific set of biomarkers that may be used to predict a patient’s response to checkpoint inhibitors. The development and utility of this multimodal approach will be presented across two posters by Biognosys and NeoGenomics at the 2022 American Association for Cancer Research (AACR) annual meeting this week. The multimodal offering will also be made available commercially for biopharma partners.

“The need of our pharma customers to access the next state-of-the-art technology to improve diagnostics and clinical trials is top priority for us,” said Gina Wallar, Ph.D., President, Pharma Services, NeoGenomics Laboratories, Inc. “Partnering with Biognosys gives us the added advantage of expanding into proteomics, data analytics and subsequent actionable results, not only in early discovery and translational research but ultimately, in clinical trials impacting patient care.”

AACR Posters

Abstract 3923 : Ubiquitin ligases implicated as predictive biomarkers for poor outcome to immunotherapy in melanoma patients

In this poster presented by Biognosys on April 13, unbiased proteomic profiling with TrueDiscovery was used to characterize melanoma patients and their responses to PD1-targeted immunotherapy. The profiling was able to identify a set of 103 proteomic biomarkers associated with ubiquitination pathways that correlate with treatment outcomes. The results were cross analyzed with the spatial tissue analysis performed via the MultiOmyx platform. These findings need to be further confirmed in orthogonal cohorts, nevertheless the data point to the possibility of more precise targeting of melanoma patients for immunotherapy.

Abstract 1267 : Dual approach using unbiased proteomics and multiplexed immunofluorescence for the detection of markers predictive for immunotherapy in melanoma patients

Despite clinical advances, durable responses to immune checkpoint inhibitors are not observed in 40-60% of melanoma patients, and current biomarkers do not clearly distinguish responders. In this study presented by NeoGenomics today, a dual proteomic and mIF profiling approach was able to comprehensively characterize melanoma patients and successfully stratify non-responders from responders based on a set of selected protein biomarkers.

To see Biognosys’ full presence at the AACR 2022 annual meeting, please refer to this press release or visit biognosys.com/aacr22.

About TrueDiscovery™

The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.

TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced Data Independent Acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.

TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment. For more information, visit truediscovery.bio.

About Biognosys

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad, Fresno and San Diego, California; Houston, Arizona, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Rolle, Switzerland, and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. For additional information about NeoGenomics, visit neogenomics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact Biognosys
Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com

Media Contact NeoGenomics, Inc.
Madhushree Ghosh
Vice-President, Global Strategic Alliances & Projects
Phone +1 858 342 2724
madhushree.ghosh@neogenomics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Holiday Data From Xsolla Shows Players Are Shopping, Gifting, and Choosing Brands Inside Video Games16.11.2026 19:00:00 EET | Press release

Xsolla (USA), Inc., a global commerce company, today announced a new data and insights report on how players shop, spend, and respond to brands during the holiday season. Titled “Why Video Games Belong in Your Holiday Commerce Strategy,” the report draws on direct answers from more than 4,000 players, gathered through opt-in rewarded surveys on Xsolla Offerwall. Players chose to take part and received a reward for sharing, which makes the data first-party and consent-based. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111104582/en/ Graphic: Xsolla The research builds on the conversation Xsolla opened at Advertising Week New York 2026 about how brands can reach players in more ways through video games. Combined with Xsolla’s insights into in-game purchasing behavior across an audience of over 300 million players, the survey shows an engaged audience with established spending habits: 84% of respondents call themselves gam

IQM Supports NVIDIA’s Work to Make Quantum Computers Schedulable in Slurm16.11.2026 18:00:00 EET | Press release

IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced at SC26 in Chicago its support for NVIDIA’s investment in making quantum processing units (QPUs) a schedulable resource in the Slurm workload manager by integrating IQM quantum computers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116814640/en/ NVIDIA is making quantum computers a schedulable resource in Slurm by integrating IQM quantum computers. NVIDIA, which has committed to keeping Slurm open source and vendor neutral, announced that Slurm 26.11 adds plugin support for Hierarchical Resources (HRES), allowing a supercomputing center to describe a QPU as a shared, cluster-level resource and connect it to external services, such as the software that manages the device. Until now, quantum computers have not fit the scheduling models Slurm uses for CPUs and GPUs, so integrations have often been built separately f

The Rock-It Company Opens New Regional Office in Nashville16.11.2026 18:00:00 EET | Press release

The Rock-It Company, a global leader in live events and luxury goods logistics, announced the opening of a new regional office in Nashville, Tennessee, reinforcing its presence in one of the world's most important live music and cultural markets. The Nashville office brings together the full Rock-It platform with dedicated offices for Rock-It Cargo, Rock-It Sports, CARS by Rock-It and DIETL by Rock-It, serving as a regional hub for the company's broader portfolio of specialty logistics offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116286387/en/ The Rock-It Company office in Nashville, Tennessee “Nashville has been a central part of our business for decades, and we see tremendous opportunity to continue building on that foundation," said Daniel Rosenthal, President and CEO of The Rock-It Company. "Our longstanding partnership with the Rock organization, combined with the expertise and relationships our teams ha

What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health16.11.2026 16:45:00 EET | Press release

We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116303495/en/ MindMetrix’s myflow platform turns pupil-based measurements into live biofeedback, with each user’s training sessions and progress shown in a dashboard. Image: MindMetrix The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live

Factbird Launches Visual Intelligence and Factbird MCP: AI That Sees the Shop Floor and Connects to Any AI Assistant16.11.2026 16:39:00 EET | Press release

Today, Factbird announces the launch of two new AI capabilities. Visual Intelligence uses cameras and AI to measure what sensors and PLCs miss. Factbird MCP lets AI assistants such as Claude, ChatGPT, and Microsoft Copilot work directly with production data in Factbird. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113769016/en/ Factbird Visual Intelligence tracking a bottling line in real time, showing filler and shrink wrapper status, line speed of 72 bottles per minute, and operator activity around the line. (AI-generated illustration) The losses that are hardest to explain happen around the machine. A station waits for material. A manual task runs long on the night shift. Each one costs a few minutes, and over a year they add up to real capacity. Factbird is a System of Action, built for manufacturers who have plenty of data and struggle to act on it. It connects production data from every line, machine, and operator

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye